Trial Profile
A Randomised, Open-label, Parallel Controlled, Multicentre, Phase 3 Clinical Trial of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer:
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jul 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Pyrotinib (Primary) ; Lapatinib
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms PHOEBE
- Sponsors Jiangsu Hengrui Medicine Co.
- 07 Jun 2022 Results of pooled analysis from (NCT01937689,NCT02361112,NCT02422199,NCT03080805) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 11 Feb 2021 Results of pre-specified interim analysis published in the Lancet Oncology
- 18 Jun 2020 Planned End Date changed from 1 Dec 2019 to 1 Mar 2021.